The Forum was attended by 8 foreign official delegations from Azerbaijan, Armenia, Kazakhstan, Kyrguz Republic, Belarus Republic, Serbia, Tajikistan, and Uzbekistan. The Russian delegation was headed by Mikhail Murashko, Minister of Health of the Russian Federation.

During the Forum the Pharmasyntez group of companies presented a line of antineoplastic drug products manufactured in the Saint Petersburg factory. 

As part of a special session moderated by Andrei Kaprin, Chief Adjunct Oncologist of the Ministry of Health (Minzdrav) of Russia, information about the first Russian original drug manufactured by the company for therapy of chronic myeloid leukemia, a new (fourth) generation tyrosine kinase BCR-ABL inhibitor Vamotinib (PF-114), which is now undergoing phase III clinical study, was presented to the participants.

'The preclinical studies and the phase I clinical study showed that Vamotinib:
– acts more selectively with respect to tyrosine kinase BCR-ABL compared to all existing drugs;
– demonstrates inhibition of tyrosine kinase BCR-ABL with T315I mutation;
– has a good tolerability and low toxicity compared to previous generations of inhibitors;
– demonstrates a high therapeutic potential, including therapy of pretreated patients with chronic myeloid leukemia who have had two or more lines of therapy, including Ponatinib’

On the last day of the Forum a tour of the Pharmasyntez-Nord factory was organized for the participants. The representatives of Ministry of Industry and Trade (Minpromtorg) of Russia, of Minzdrav of Russia, of Federal Service for Supervision in Healthcare, and the honourable guests of the Forum – the officials of CIS delegations – had a view of workshops for production of cytostatic agents and biopharmaceuticals, as well as R&D Center for biopharmaceuticals development.